EUVIMEDEUVIMED entdecken
Crossref

L26/P-422 COmbining Interventions of fertility preservation to Mitigate fertility loss after BReAst cancer (COIMBRA): a multicenter randomized pilot study

C. De Roo, M. Soares, I. Segers, L. Dhaenens, I. De Quick, D. Stoop, M. De Vos

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.756 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von C. De Roo und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question What is the impact on oocyte yield when ovarian stimulation before chemotherapy in breast cancer patients is preceded by ovarian cortex biopsy? Summary answer Although ovarian biopsy reduces follicle output rate and oocyte yield after stimulation, this strategy remains feasible and could be a suitable option in oncofertility practice. What is known already Oocyte or embryo vitrification remain the gold standard for fertility preservation before systemic cancer treatment. If time pressure precludes the option of ovarian stimulation for oocyte/embryo vitrification, then ovarian cortex cryopreservation can be offered. Combining different fertility preservation strategies may have the potential to enhance fertility options after cancer treatment, by spreading the sources of gametes and hence diluting the failure risk for the patient, whose chances for genetically own offspring would otherwise be dependent on one single source of gametes only. A previous retrospective study suggested that bilateral ovarian biopsy did not affect oocyte yield compared with age-matched controls Study design, size, duration This multicentric prospective randomized controlled study established whether unilateral ovarian biopsy (removal of approximately 20% of ovarian cortex, estimated from the initial pelvic ultrasound) does not have a negative impact on the Follicle Output rate (FORT) of the biopsied ovary and on the average number of mature oocytes at oocyte retrieval after ovarian stimulation. A non-inferiority margin not exceeding two metaphase II oocytes was predefined. Patients were included between March 2021 and October 2023. Participants/materials, setting, methods Patients underwent unilateral biopsy of ovarian cortex via laparoscopy, after eligibility confirmation and informed consent. The biopsy side (right or left) was randomized on day of laparoscopy. Ovarian stimulation was initiated in the evening of surgery with corifollitropin alfa 0.15mg, followed from day 8 by individualized doses of follitropin beta, within a fixed GnRH antagonist protocol with letrozole 5mg cotreatment. Oocyte retrieval was performed 36 hours after dual ovulation trigger (GnRH agonist0.2mg and hCG 250µg). Main results and the role of chance Nine young breast cancer patients (29.8+/-3.9 years old) were included between cancer diagnosis and the start of oncologic treatment. All patients had a normal ovarian reserve, with 9.0 +/-3.7 (mean +/- standard deviation) antral follicles in the right ovary, 7.1 +/- 2.8 in the left one, and anti-Müllerian hormone serum levels of 2.24 +/- 2.4 µg/L. The ovarian biopsy fragment obtained by laparoscopy had a volume of 677.83 +/- 736.0 mm³ and a weight of 458.3+/- 201.4 mg. Ovarian stimulation took 11.3 +/- 1.3 days using CFA followed by a total dose of 802.8 +/- 401.6 IU of follitropin beta. The follicle output rate (FORT) defined as pre-ovulatory follicles (16-22 mm) divided by the antral follicle count and multiplied by 100 was 27.8+/- 31.0% at the operated side compared to 82.3 +/- 12.8% at the non-operated side. This represents an absolute reduction of 54.5 percentage points and a relative decrease of 66% compared to the non-operated side. The number of harvested COCs was 5.0 +/- 2.6, with 3.7 +/- 1.7 metaphase II (MII) oocytes at the operated side and 9.3 +/- 5.6 COC’s with 7.2 +/- 5.3 MII at the non-operated side. All interventions were performed without any complications. Limitations, reasons for caution While the non-inferiority power analysis estimated that 41 patients were required, recruitment was discontinued before this number was reached. Patients frequently expressed reluctance and felt overwhelmed by the proposed combination of ovarian biopsy and stimulation, which was considered too burdensome given the recent diagnosis and impending initiation of oncological therapy. Wider implications of the findings Follicular output rate and oocyte yield from a biopsied ovary appeared to be reduced in breast cancer patients. Nevertheless, the combination of ovarian cortex freezing and oocyte/embryo vitrification may enhance fertility options after cancer and creates the future option of ovarian tissue grafting in case of early menopause. Trial registration number Yes

Zitieren

APA

Roo, C. D., Soares, M., Segers, I., Dhaenens, L., Quick, I. D., Stoop, D., & Vos, M. D. (2026). L26/P-422 COmbining Interventions of fertility preservation to Mitigate fertility loss after BReAst cancer (COIMBRA): a multicenter randomized pilot study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.756

Vancouver

Roo CD, Soares M, Segers I, Dhaenens L, Quick ID, Stoop D, et al. L26/P-422 COmbining Interventions of fertility preservation to Mitigate fertility loss after BReAst cancer (COIMBRA): a multicenter randomized pilot study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.756

BibTeX
@article{Roo2026,
  author = {Roo, C. De and Soares, M. and Segers, I. and Dhaenens, L. and Quick, I. De and Stoop, D. and Vos, M. De},
  title = {L26/P-422 COmbining Interventions of fertility preservation to Mitigate fertility loss after BReAst cancer (COIMBRA): a multicenter randomized pilot study},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.756}
}
Kostenlos starten →